Small cell neuroendocrine cervical cancer (SCNCC) is a highly aggressive tumor, and there is currently no standard treatment for recurrent SCNCC. We treated three patients with recurrent SCNCC who had received prior etoposide/cisplatin chemotherapy with single-agent amrubicin (35 mg/m2, days 1–3). Partial response was achieved in one patient who had no signs of disease progression 14 months after commencing amrubicin. This patient received a total of 10 cycles of amrubicin every 3 weeks, with acceptable adverse effects. Amrubicin treatment was unsuccessful and was discontinued in the other two patients; one received a total of five cycles of amrubicin with acceptable adverse effect, but amrubicin was discontinued because of disease progression, and the other discontinued amrubicin after only two cycles because of grade 4 neutropenia/thrombocytopenia.